Safety and Efficacy of Budesonide During Pregnancy in Women With Autoimmune Hepatitis
2020; Lippincott Williams & Wilkins; Volume: 73; Issue: 6 Linguagem: Inglês
10.1002/hep.31634
ISSN1527-3350
AutoresMussarat N. Rahim, Shaolu Ran, Sital Shah, Sarah Hughes, Michael A. Heneghan,
Tópico(s)Liver Disease and Transplantation
ResumoHepatologyVolume 73, Issue 6 p. 2601-2606 Clinical Observations in Hepatology Safety and Efficacy of Budesonide During Pregnancy in Women With Autoimmune Hepatitis Mussarat N. Rahim, Mussarat N. Rahim Institute of Liver Studies, King's College Hospital, London, United KingdomSearch for more papers by this authorShaolu Ran, Shaolu Ran Institute of Liver Studies, King's College Hospital, London, United KingdomSearch for more papers by this authorSital Shah, Sital Shah Institute of Liver Studies, King's College Hospital, London, United KingdomSearch for more papers by this authorSarah Hughes, Sarah Hughes Institute of Liver Studies, King's College Hospital, London, United Kingdom Department of Gastroenterology and Hepatology, St George's University Hospitals NHS Foundation Trust, London, United KingdomSearch for more papers by this authorMichael A. Heneghan, Corresponding Author Michael A. Heneghan michael.heneghan@nhs.net Institute of Liver Studies, King's College Hospital, London, United Kingdom ADDRESS CORRESPONDENCE AND REPRINT REQUESTS: Michael A. Heneghan, M.D., M.Med.Sc., F.R.C.P.I. Institute of Liver Studies, King's College Hospital NHS Foundation Trust Denmark Hill London, SE5 9RS, United Kingdom E-mail: michael.heneghan@nhs.net Tel.: +442032993369Search for more papers by this author Mussarat N. Rahim, Mussarat N. Rahim Institute of Liver Studies, King's College Hospital, London, United KingdomSearch for more papers by this authorShaolu Ran, Shaolu Ran Institute of Liver Studies, King's College Hospital, London, United KingdomSearch for more papers by this authorSital Shah, Sital Shah Institute of Liver Studies, King's College Hospital, London, United KingdomSearch for more papers by this authorSarah Hughes, Sarah Hughes Institute of Liver Studies, King's College Hospital, London, United Kingdom Department of Gastroenterology and Hepatology, St George's University Hospitals NHS Foundation Trust, London, United KingdomSearch for more papers by this authorMichael A. Heneghan, Corresponding Author Michael A. Heneghan michael.heneghan@nhs.net Institute of Liver Studies, King's College Hospital, London, United Kingdom ADDRESS CORRESPONDENCE AND REPRINT REQUESTS: Michael A. Heneghan, M.D., M.Med.Sc., F.R.C.P.I. Institute of Liver Studies, King's College Hospital NHS Foundation Trust Denmark Hill London, SE5 9RS, United Kingdom E-mail: michael.heneghan@nhs.net Tel.: +442032993369Search for more papers by this author First published: 14 November 2020 https://doi.org/10.1002/hep.31634Citations: 1 M.A.H. is supported by an EASL Registry Grant and King's College Hospital Charity (Orpin Bequest). Potential conflict of interest: Dr. Heneghan consults for Novartis and Roche. He is on the speakers' bureau for Falk and Intercept. Dr. Hughes advises for Dr. Falk. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Citing Literature Volume73, Issue6June 2021Pages 2601-2606 RelatedInformation
Referência(s)